Ovarian cancer is the gynaecological malignancy with the highest mortality worldwide and high-grade serous ovarian cancer (HGSOC) is the most common and malignant form of ovarian cancer, making it the most clinically relevant form of ovarian cancer to investigate.1 Treatment options for HGSOC remain limited but recently new therapies such as PARP (poly-ADP-ribose polymerase) inhibitors,2 immune checkpoint inhibitors3 and VEGF (vascular endothelial growth factor) inhibitors4 have shown promise for improving the outlook of the disease. Here, VEGFA is linked to ovarian carcinoma.